April 17 (Reuters) - The U.S. Food and Drug
Administration website showed that most doses of Eli Lilly's ( LLY )
diabetes drug Mounjaro and weight-loss drug Zepbound
would be available in limited amounts through the second quarter
of this year due to increased demand.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Devika
Syamnath)